Scandion Oncology: Our comment on CORIST part 2 top-line data - Redeye

Redeye comments on Scandion communicating CORIST part 2 top-line results. While we judge that top-line results confirm safety and tolerability of combining SCO-101 and FOLFIRI, no partial responses have been observed thus far. Therefore, we judge that CORIST part 2 top-line data are incrementally negative.

Länk till analysen i sin helhet: https://www.redeye.se/research/856882/scandion-oncology-our-comment-on-corist-part-2-top-line-data?utm_source=finwire&utm_medium=RSS